IP Library Granted Patent US 9,416,192
Granted Patent B2
US 9,416,192 · App. 13/057,709 · Granted Aug 16, 2016

Pharmaceutical composition for treatment and prevention of cancers

Inventors: Fumiyoshi Okano (Kanagawa, JP); Takayoshi Ido (Kanagawa, JP); Takanori Saito (Kanagawa, JP); Shinichi Kobayashi (Kanagawa, JP)
Assignee: TORAY INDUSTRIES, INC.
C07K16/3015A61K39/39558C07K16/3053C07K2317/24C07K2317/565C07K2317/732C07K2317/734
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,416,192
App. No.
13/057,709
Granted
Aug 16, 2016
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids.

Claims (8)

1. A method for treatment of a CAPRIN-1 expressing cancer in a subject, comprising administering to the subject an antibody or antigen-binding fragment thereof having an immunological reactivity with a CAPRIN-1 protein which has the amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 30, wherein the antibody or fragment specifically binds the CAPRIN-1 protein expressed on the cell surface of the cancer.

2. A method for treatment of a CAPRIN-1 expressing cancer in a subject, comprising administering to the subject a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof having an immunological reactivity with a CAPRIN-1 protein which has the amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 30, wherein the antibody or fragment thereof specifically binds the CAPRIN-1 protein expressed on the cell surface of the cancer.

3. The method according to claim 1 , wherein the cancer is damaged by an antibody-dependent cell-mediated cytotoxicity (ADCC) activity of the antibody.

4. The method according to claim 1 , wherein the antibody is a monoclonal antibody or polyclonal antibody.

5. The method according to claim 1 , wherein the antibody is a human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a bispecific antibody.

6. The method according to claim 2 , wherein the cancer is damaged by an antibody-dependent cell-mediated cytotoxicity (ADCC) activity of the antibody.

7. The method according to claim 2 , wherein the antibody is a monoclonal antibody or polyclonal antibody.

8. The method according to claim 2 , wherein the antibody is a human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a bispecific antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2011
From: OKANO, FUMIYOSHI; IDO, TAKAYOSHI; SAITO, TAKANORI; KOBAYASHI, SHINICHI
To: TORAY INDUSTRIES, INC.
Reel/Frame 025755/0796 →
Priority Claims (2)
JP 2008-201928 · Aug 5, 2008 · national
JP 2009-087285 · Mar 31, 2009 · national
Continuity (1)
Related Publication 20110256144A1 · Oct 20, 2011